Coronavirus pharma news roundup – 04/06/20
FDA clears emergency use of Roche test for COVID-19 ‘cytokine storm’
5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed
Wait for More Clarity Before Buying Gilead Stock, Says Analyst
Estimating a US price tag of $5K per course, remdesivir is set to make billions for Gilead, says key analyst
Gilead’s next step on coronavirus
Study finds COVID-19 convalescent plasma therapy safe, with 76% patients improving
Gilead Sinks 3% On New Remdesivir Data; Analysts Stay Sidelined
New remdesivir study leaves clinicians guessing about its efficacy
Solubilizer Captisol enables body to absorb authorized COVID-19 drug therapy
Coronavirus news roundup – 29/05/2020
Atriva takes MEK inhibitor into phase 2 for COVID-19
Gilead's Remdesivir May Be a Coronavirus Silver Bullet -- But It's Already Baked in the Stock Price
UK okays early access to Gilead’s remdesivir in seriously ill COVID-19 patients
Regeneron Announces Secondary Offering Pricing At $515/Share
Sorrento’s COVID-19 Antidote Could be a Game Changer, Says Analyst
Eli Lilly, Junshi Biosciences To Start Human Testing Of Covid-19 Antibodies By Q2
Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery
Merck Takes 3 Major Shots at COVID-19
Regeneron To Repurchase $5 Billion Stake From Sanofi
Gilead’s Remdesivir Most ‘Beneficial’ In Covid-19 Patients Who Need Extra Oxygen, Study Shows
Researchers define exactly what they saw in the first positive remdesivir study for Covid-19. But what's that worth to Gilead?
Gilead, Galapagos claim PhIIb/III win for filgotinib in ulcerative colitis — which pales in comparison to rivals
Gilead Still Holds the Winning Hand, Says 5-Star Analyst
Aldeyra Explodes 30% After-Hours Ahead Of Covid-19 Update Today
Dynavax Explodes 40% In Pre-Market On Phase 1 Covid-19 Vaccine News
Moderna Prices $1.3B Equity Offering at $76/Share
Buffett And Bank Stocks; A Bullish Indicator For Berkshire
Machine that oxygenates blood may help critically ill COVID-19 patients, according to WVU study
Moderna Spikes 21% Amid “Positive” Early-Stage Covid-19 Vaccine Data